What Enara Bio does

Enara Bio is a privately held UK biopharmaceutical company headquartered at Oxford Science Park that is pioneering the discovery of a novel class of cancer-specific antigens called Dark Antigens, derived from the approximately 98% of the human genome historically considered non-coding or genomic dark matter. The company operates two integrated proprietary platforms: EDAPT (Enara Dark Antigen Platform Technology), a discovery engine that combines proprietary computational biology with multi-modal proteomics (DDA-MS, PRM-MS, DIA-MS), Ribo-seq, and RNA-ISH validation across primary tumor and healthy tissue samples; and EnTiCE, a protein-engineering toolkit for designing and optimizing bispecific T-cell engagers (TCEs) with high-affinity tumor antigen binders, optimized anti-CD3 kinetics, and silenced Fc backbones for half-life extension. The lead clinical candidate, ENA101, is a first-in-class bispecific TCE targeting the DARKFOX-A3 peptide presented by HLA-A*03:01 — a Dark Antigen encoded by a previously undiscovered alternative open reading frame within FOXM1 with reported expression across lung, breast, GI, head and neck, and ovarian cancers — and is currently advancing through IND-enabling studies with IND submission planned for the second half of 2026. Preclinical data presented at AACR 2026 demonstrated robust T-cell activation and complete tumor regression in multiple solid tumor xenograft models.

Enara generates revenue today exclusively through licensing and milestone payments under a strategic collaboration with Boehringer Ingelheim, which has exercised options to license multiple Dark Antigen targets for off-the-shelf therapeutic cancer vaccines in non-small cell lung cancer and at least one undisclosed solid tumor indication. The company is pre-revenue with respect to product sales, has 51-100 employees, and is backed by a syndicate of life science investors including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, SV Health Investors, and the Francis Crick Institute. Founded on the science of co-founder Professor George Kassiotis at the Francis Crick Institute, Enara has built an external research ecosystem through academic collaborations (Francis Crick Institute, George Washington University, University of Cambridge) and a 2025 antibody discovery partnership with Adimab to support pipeline expansion beyond ENA101 into undisclosed TCE programs for solid tumors, with melanoma and ovarian cancer indications explicitly flagged as available for partnering.

Name

Enara Bio

Legal name

Enara Bio Ltd

Website

https://enarabio.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Enara Bio is a pre-revenue UK biopharmaceutical company developing first-in-class bispecific T-cell engagers that target cancer-specific Dark Antigens derived from genomic dark matter, with lead candidate ENA101 advancing through IND-enabling studies for solid tumor indications.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Cancer immunotherapy
• Bispecific T-cell engagers
• Dark antigen discovery
• TCR-based immunotherapies
• Oncology therapeutics

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Licensing and Milestone Payments: Enara Bio generates revenue through licensing agreements with pharmaceutical partners. Boehringer Ingelheim has exercised options to license multiple Dark Antigen targets, triggering milestone payments. The collaboration includes licensing for non-small cell lung cancer vaccines and an additional undisclosed solid tumor program.
2. Future Product Sales: Pre-revenue biopharmaceutical company developing bispecific T-cell engagers for solid tumors. ENA101 is the lead clinical candidate advancing toward clinical trials, with potential for future commercial sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Enara Bio is a biopharmaceutical company that discovers and develops cancer immunotherapies targeting a novel class of tumor-specific antigens called Dark Antigens, which are derived from previously unexplored genomic dark matter. The company operates two proprietary platforms—EDAPT for discovering and validating Dark Antigens, and EnTiCE for optimizing bispecific T-cell engagers—and is advancing its lead clinical candidate ENA101, a first-in-class bispecific T-cell engager targeting the DARKFOX antigen, toward IND submission in the second half of 2026.

Product overview

Enara Bio is a biopharmaceutical company pioneering the discovery of novel Dark Antigens and development of bispecific T-cell engagers for solid tumors. The company operates two integrated proprietary platforms: EDAPT® (discovery engine) for identifying cancer-specific antigens from genomic dark matter, and EnTiCE® (development platform) for optimizing bispecific T-cell engagers. The lead clinical candidate ENA101 is a first-in-class bispecific T-cell engager targeting DARKFOX®, a novel Dark Antigen derived from an alternative open reading frame of FOXM1. The company has a strategic collaboration with Boehringer Ingelheim for Dark Antigen licensing in lung cancer and other solid tumors, with multiple undisclosed programs in development for melanoma and ovarian cancer available for partnering.

Differentiator

Problem solved

Functional benefit

Brands

• EDAPT®: Enara Dark Antigen Platform Technology - an industry-leading discovery engine for Dark Antigens
• EnTiCE®
• Dark Antigens®
• DARKFOX®

Products and services

• ENA101 First-in-class bispecific T-cell engager targeting the DARKFOX-A3 peptide presented by HLA-A*03:01, designed to selectively redirect T cells to DARKFOX-expressing tumor cells while sparing normal tissues. It is the company's lead clinical candidate for solid tumors, intended for licensing or co-development with pharmaceutical partners.
• DARKFOX A novel cancer-specific Dark Antigen target encoded by an alternative open reading frame within FOXM1, representing a new class of highly tumor-specific targets derived from the dark proteome. Licensed or co-developed with pharmaceutical partners such as Boehringer Ingelheim for immunotherapy development.
• Dark Antigens Portfolio A portfolio of novel tumor-specific antigens derived from genomic dark matter, licensed to pharmaceutical partners such as Boehringer Ingelheim for development of off-the-shelf therapeutic cancer vaccines across non-small cell lung cancer and other solid tumor indications.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered secondary and core.

• George Washington UniversitysecondaryStrategic or Co-development Partner · 18 February 2025Research collaboration with the laboratory of Katherine Chiappinelli, PhD, at GW Cancer Center to identify drugs that can enhance Dark Antigen expression (priming tumors for maximal clinical response to Dark Antigen-targeting immunotherapies) and to study the underlying function of certain Dark Antigens in cancer biology.
• Boehringer IngelheimcoreStrategic or Co-development Partner · 3 October 2024Strategic collaboration and licensing agreement leveraging Enara's EDAPT platform to discover and validate Dark Antigens in various tumor types. Boehringer has exercised options to license multiple Dark Antigens for developing novel off-the-shelf therapeutic cancer vaccines, including a major milestone for non-small cell lung cancer (NSCLC) and an additional undisclosed solid tumor program. Enara receives milestone payments under this collaboration.
• Francis Crick InstitutecoreStrategic or Co-development PartnerOne of Enara Bio's founders, Professor George Kassiotis, is a Group Leader at the Francis Crick Institute. His discovery of novel tumor-specific antigens derived from reactivated endogenous retroviral sequences formed the foundational science behind Enara Bio. The Institute is also an investor in the company.
• University of CambridgesecondaryStrategic or Co-development PartnerCollaboration with the University's Department of Pathology for the use of RNA-based techniques to characterize the expression of Dark Antigens in tumor cells and healthy tissue.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Immunocore: UK-based biotech pioneering TCR-based bispecific immunotherapies (ImmTAC platform), with tebentafusp approved for uveal melanoma. Enara's CSO Joseph Dukes and CEO Kevin Pojasek both came from Immunocore, making it the most direct technology and personnel comparable.
• Adaptimmune Therapeutics: Clinical-stage biotech developing engineered TCR cell therapies (SPEAR T-cells) targeting solid tumors, including NY-ESO and MAGE-A4 programs. Comparable in its focus on TCR-based solid tumor therapeutics and similar clinical development stage.
• Harpoon Therapeutics (acquired by Merck): Developed tri-specific T-cell engagers (TriTAC) for solid tumors, including HPN328 (DLL3) and prostate cancer programs. Directly comparable in TCE format, solid tumor focus, and small-cap biotech profile before Merck's acquisition.
• Macrogenics: Clinical-stage biotech with multiple bispecific antibody platforms (DART, TRIDENT) targeting solid tumors and hematologic malignancies. Closely comparable in modality (bispecific antibodies) and oncology focus.
• Crescendo Biologics: Oxford/Cambridge UK-based biotech developing T-cell engagers (TCEs) based on a proprietary VH domain platform (Humabody). Direct peer as a UK-based, small-cap TCE biotech with a platform-engineering focus on solid tumor targets.
• TScan Therapeutics: Clinical-stage biotech developing TCR-based immunotherapies identified through a high-throughput target screening platform. Directly comparable in the use of proprietary discovery platforms to identify novel TCR targets for solid tumor therapy.

Broad incumbents

• Amgen: Established biopharma with the pioneering BiTE (bispecific T-cell engager) platform, including the approved Blincyto. Comparable as the dominant incumbent in the TCE modality that Enara's ENA101 competes against in solid tumors.
• Regeneron Pharmaceuticals: Develops bispecific antibodies (including linvoseltamab and odronextamab) and has deep oncology pipelines. Comparable as a major incumbent advancing multiple bispecific antibody programs, with Enara's CMO Dr. Drutman having prior tenure at Regeneron.

Emerging players

• Black Diamond Therapeutics: Clinical-stage biotech using computational platforms to discover novel precision oncology targets, including allosteric and oncogenic mutant-selective targets. Comparable as a platform-based, target-discovery-focused oncology biotech pursuing novel tumor-specific antigens.
• Terns Pharmaceuticals: Clinical-stage oncology biotech with small-molecule and biologic programs including T-cell engagers. Comparable as a small-cap oncology platform pursuing differentiated mechanisms for solid tumors, with a focus on combining modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/enara_bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enara Bio